Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEpigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features
Molecular Carcinogenesis, 06/30/09
Kim DS et al. - In a trial to explore the role of Homeobox A5 (HOXA5) in non-small cell lung cancer (NSCLC), it was shown that downregulation of the HOXA5 gene by aberrant promoter methylation occurs in the vast majority of NSCLCs and it may play a role in the pathogenesis of NSCLC.
Methods- Methylation status of the promoter region of the HOXA5 gene was investigated in NSCLCs using nested and standard methylation-specific PCR (MSP).
- Methylation status with clinicopathological features was correlated.
- With standard MSP analysis, HOXA5 methylation was found in 113 (81.3%) of 139 NSCLCs and 72 (51.8%) in their corresponding nonmalignant lung tissues.
- RT-PCR and immunohistochemical analysis showed that HOXA5 methylation correlates with gene expression.
- In pts with stage I disease, HOXA5 methylation was more frequent in smokers than in never-smokes.
- There was no influence of HOXA5 methylation on survival in all NSCLCs or at stages II-IV.
- In patients with stage I disease, HOXA5 methylation was associated with a borderline significantly worse survival.
Related Articles
Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related Non-Small Cell Lung Cancer Through Aberrant Methylation and Alterations of EGFR Signaling
Annals of Surgical Oncology, 10/23/09
Relevance Score: 89%
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Relevance Score: 87%
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
Journal of Clinical Oncology, 10/29/09
Relevance Score: 85%
Expression and Significance of Clusterin in Anip973/CDDP Cell Lines
Chinese Journal of Lung Cancer, 10/23/09
Relevance Score: 85%
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 85%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Clinical Cancer Research, 12/11/09
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Clinical Cancer Research, 12/11/09
Platelets release novel thiol isomerase enzymes which are recruited to the cell surface following activation
British Journal of Haematology, 12/11/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer
Investigational New Drugs, 12/11/09
Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy
Cancer Chemotherapy and Pharmacology, 12/11/09
Stage I nonsmall cell lung cancer in patients aged >=75 years
Cancer, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor